Open innovation
In the fiercely competitive world of drug discovery and development, secrecy is no longer as important as it once was. As it has become more difficult and costly to produce therapies, competitors have begun to view greater collaboration and openness as a way to accelerate and improve the efficiency of research.
For more on open innovation from nature.com, see: nature.com/subjects/drug-discovery-and-development
Free full access
Nature is pleased to acknowledge financial support from Boehringer Ingelheim in producing this Outlook. The sponsor retains sole responsibility for the following messages.
In November 2015, Boehringer Ingelheim announced its new research and development (R&D) strategy and five-year R&D investment programme. As part of this strategy, we recognize that open innovation plays an essential part in the discovery of new medicines. Indeed, Boehringer Ingelheim has been systematically opening its innovation process to the outside world. We acknowledge that our success will depend upon the ability to access innovative ideas for new therapeutic approaches and disease mechanisms, and to combine these with proven internal strengths in drug discovery and development. Thus Boehringer Ingelheim has recently redefined its Discovery Research Strategy to foster a greater culture of innovation in the organization and enhance its ability to access breakthrough science from around the world. This strategy is based on three guiding principles: building on our company’s existing strengths; creating synergies; and capturing emerging science. Opening the innovation process is a fundamental part of our drug discovery activities. Boehringer Ingelheim is pleased to support this Outlook to help highlight the variety of innovative approaches that are being pursued by the scientific community. Please join us in celebrating the many exciting ways that scientists are lighting up the discovery of new medicines with the power of open innovation.
